Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Mayne Pharma Group ( (AU:MYX) ) has provided an announcement.
The Panel declared unacceptable circumstances in Mayne Pharma’s dealings with Cosette Pharmaceuticals, Inc., following Cosette’s change of intentions regarding the Salisbury Site. This decision impacts the market’s perception of the control over Mayne Pharma, highlighting concerns about competitive and informed market principles. The Panel’s orders require Cosette to comply with conditions related to the Salisbury Site, ensuring transparency and adherence to initial disclosures.
The most recent analyst rating on (AU:MYX) stock is a Hold with a A$5.00 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
More about Mayne Pharma Group
Mayne Pharma Group Limited is an ASX-listed pharmaceuticals company with a primary focus on the US market. It also operates in Australia, where it maintains a manufacturing site in Salisbury, South Australia, employing over 200 people.
Average Trading Volume: 457,953
Technical Sentiment Signal: Sell
Current Market Cap: A$394M
See more insights into MYX stock on TipRanks’ Stock Analysis page.